



To whom it may concern,

We are writing this letter in order to introduce you to the new European Project for expedited vaccine development, VACCELERATE; If after reading this letter you are interested in taking part of this project, please follow the instructions to register.

VACCELERATE is a new clinical research network for the conduct of COVID-19 vaccine clinical trials that was launched on February 2021.

This consortium is integrated by academic institutions from 26 countries across Europe, funded by the European Commission and coordinated by the University of Cologne. This network will serve as an entry-point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 & 3 trials in Europe.

The objective of VACCELERATE is to gather expertise and resources in order to speed up future or already working vaccine development programs. These are the main issues that will be addressed by Vaccelerate:

- Study Vaccine efficacy in virus variants, children, pregnant women, immune-compromised patients.
- Study Vaccine efficacy of combination of different vaccines.
- Establishment of European Volunteer Registry for fast recruitment of trial participants.
- Conduct of capacity mapping of new clinical trial sites and laboratories.
- Identify needs for training and quality management for harmonized vaccine trials.

We are extending this invitation letter to all adult clinical sites, academic sites, primary/ secondary care centers that may be interested in participating in COVID-19 phase 2/3 trials within the context of the VACCELETATE EUROPEAN PLATFORM.

If you are interested, we encourage you to register in the EUVAP platform. This is the link where you can access the registration process: <https://www.euvap.eu/> ; you will be asked to fill out a feasibility questionnaire which doesn't last longer than 15 minutes.

Once you register in EUVAP, you could potentially be considered by sponsors to perform clinical trials based on specific vaccine trial requirements; nevertheless, by registering in EUVAP, you don't have any obligation to participate in the upcoming vaccines trials.

We appreciate your time reading this letter and we look forward to collaborate with you in the future.

Please contact robert.flisiak1@gmail.com if you have further questions,

Sincerely,

Prof. Robert Flisiak

VACCELERATE NATIONAL COORDINATOR - POLAND